Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth.
Walbert received his Bachelor of Arts in business from Muhlenberg College in Allentown, Pa. He serves as chairman of the board of Exicure Inc. and serves on the board of Aurinia Pharmaceuticals Inc. and the Illinois Biotechnology Innovation Organization (iBIO). He is a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served on the boards of directors of Raptor Pharmaceutical Corp., a public biopharmaceutical company, from 2010 to 2014; XOMA Corporation, a public biotechnology company, from 2011 to 2017; and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2016 to 2018.
What is Timothy P. Walbert's net worth?
The estimated net worth of Timothy P. Walbert is at least $50.69 million as of June 3rd, 2022. Mr. Walbert owns 435,826 shares of Horizon Therapeutics Public stock worth more than $50,686,564 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Walbert may own. Additionally, Mr. Walbert receives a salary of $3,500,000.00 as CEO at Horizon Therapeutics Public. Learn More about Timothy P. Walbert's net worth.
How old is Timothy P. Walbert?
What is Timothy P. Walbert's salary?
As the CEO of Horizon Therapeutics Public Limited, Mr. Walbert earns $3,500,000.00 per year. There are 2 executives that earn more than Mr. Walbert. The highest earning executive at Horizon Therapeutics Public is Mr. Sean M. Clayton J.D., Exec. VP & Gen. Counsel, who commands a salary of $7,030,000.00 per year. Learn More on Timothy P. Walbert's salary.
How do I contact Timothy P. Walbert?
Has Timothy P. Walbert been buying or selling shares of Horizon Therapeutics Public?
Timothy P. Walbert has not been actively trading shares of Horizon Therapeutics Public during the last ninety days. Most recently, Timothy P. Walbert sold 25,000 shares of the business's stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $92.34, for a transaction totalling $2,308,500.00. Following the completion of the sale, the chief executive officer now directly owns 435,826 shares of the company's stock, valued at $40,244,172.84. Learn More on Timothy P. Walbert's trading history.
Who are Horizon Therapeutics Public's active insiders?
Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.
